ArticleThe oncologist2023
Characterization of Gut Microbiome Composition in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy.
Article in The oncologist, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 20 citations in OpenAlex.
- Microbiome and Response to Therapy in Triple Negative Breast Cancer: A Systematic Review.Oncology research · 2026Pooled it
- Unravelling novel microbial players in the breast tissue of TNBC patients: a meta-analytic perspective.NPJ biofilms and microbiomes · 2025Pooled it
- Guideline for designing microbiome studies in neoplastic diseases.GeroScience · 2024Guideline
- Gut microbiota diversity is prognostic and associated with benefit from chemo-immunotherapy in metastatic triple-negative breast cancer.Molecular oncology · 2025Trial
- Modulation of the response to immunotherapy in triple-negative breast cancer: the role of the microbiota and microbial metabolites in the tumor microenvironment.Gut microbes · 2026Review
- The landscape of the intestinal microbiome among patients with newly diagnosed invasive breast cancer and ductal carcinoma in situ (DCIS).NPJ breast cancer · 2026Article
- Dynamic biomarkers in hormone receptor-positive/HER2-negative breast cancer trials: a new hope for precision oncology.NPJ breast cancer · 2026Review
- Host-microbiome interactions in breast cancer progression and treatment response.Frontiers in medicine · 2026Review
- Microbiome-based probiotic intervention to reduce chemotherapy-induced gastrointestinal toxicity.Frontiers in cellular and infection microbiology · 2026Article
- Microbiome-Driven Mechanisms in Breast Cancer: Emerging Evidence From Gut Microbial Signatures to Therapeutic Response.BioMed research international · 2026Review
- Dual Biological Effects and Mechanisms of Gut Microbiota in Breast Cancer: A Review.Current pharmaceutical biotechnology · 2026Review
- Dynamic changes and clinical significance of the gut microbiota and serum metabolites in breast cancer onset, progression and chemotherapy intervention.Frontiers in oncology · 2026Article
- Beyond the tumor: the role of the gut microbiome in triple-negative breast cancer.Frontiers in oncology · 2026Review
- Optimizing breast cancer chemotherapy by harnessing gut microbiota with insights from artificial intelligence.NPJ biofilms and microbiomes · 2025Review
- Race-related host and microbe transcriptomic signatures in triple-negative breast cancer.NPJ breast cancer · 2025Article
- Review
- The microbiota in breast cancer: dysbiosis, microbial metabolites, and therapeutic implications.American journal of cancer research · 2025Review
- Baseline gut microbiome alpha diversity predicts chemotherapy-induced gastrointestinal symptoms in patients with breast cancer.NPJ breast cancer · 2024Article
- Microbiome in Cancer Development and Treatment.Microorganisms · 2023Review
- Gut microbiome influences incidence and outcomes of breast cancer by regulating levels and activity of steroid hormones in women.Cancer reports (Hoboken, N.J.) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPatients with triple-negative breast cancer (TNBC) achieving a pathological complete response (pCR) after neoadjuvant chemotherapy have a better event-free survival. The role of gut microbiome in early TNBC is underexplored.
methodsMicrobiome was analyzed by 16SrRNA sequencing.
resultsTwenty-five patients with TNBC treated with neoadjuvant anthracycline/taxane-based chemotherapy were included. Fifty-six percent achieved a pCR. Fecal samples were collected before (t0), at 1 (t1), and 8 weeks (t2) from chemotherapy. Overall, 68/75 samples (90.7%) were suitable for microbiome analysis. At t0, pCR group showed a significantly higher α-diversity as compared with no-pCR, (P = .049). The PERMANOVA test on β-diversity highlighted a significant difference in terms of BMI (P = 0.039). Among patients with available matched samples at t0 and t1, no significant variation in microbiome composition was reported over time.
conclusionsFecal microbiome analysis in early TNBC is feasible and deserves further investigation in order to unravel its complex correlation with immunity and cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.